1)Bressler NM;Treatment of Age-Related Macular Degeneration with Photodynamic Therapy(TAP)Study Group:Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198-207, 2001
2)Verteporfin in Photodynamic Therapy Study Group(VIP):Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration:two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in photodynamic therapy report 2. AM J Ophthalmol 131:541-560, 2001
3)Japanese Age-Related macular Degeneration Trial(JAT)Study Group:Japanese age-related degeneration trial:1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. AM J Ophthalmol 136:1049-1061, 2003
4)Rosenfeld PJ, Brown DM, Heier JS et al;MARINA Study Group:Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431, 2006
5)Brown DM, Kaiser PK, Michels M et al;ANCHOR Study Group:Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444, 2006
6)Kaiser PK, Boyer DS, Cruess AF et al;DENALI Study Group:Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration:twelve month results of the DENALI study. Ophthalmology 119:1001-1010, 2012
7)Larsen M, Schmidt-Erfurth U, Lanzetta P et al;MONT BLANC Study Group:Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration:twelve-month MONT BLANC study results. Ophthalmology 119:992-1000, 2012
8)Koh A, Lee WK, Chen LJ et al:EVEREST study:Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453-1464, 2012
9)Koh A, Lai TYY, Takahashi K et al;EVERESTⅡ Study Group:Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy:a randomized clinical trial. JAMA Ophthalmol 135:1206-1213, 2017
10)Nowak-Sliwinska P, van den Bergh H, Sickenberg M et al:Photodynamic therapy for polypoidal choroidal vasculopachy. Prog Retin Eye Res 37:182-199, 2013
11)Dugel PU, Koh A, Ogura Y et al;HAWK and HARRIER Study Investigators:HAWK and HARRIER:phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72-84, 2020
12)Dugel PU, Singh RP, Koh A et al:HAWK and HARRIER:ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89-99, 2021
13)Bilgic A, Kodjikan L, Srivastava S et al:Initial pro re nata broluizumab for exudative AMD:the PROBE study. J Clin Med 10:4153, 2021
14)Bilgick A, Kodjikian L, March de Ribot F et al:Real-world experience with brolucizumab in wet-age related macular degeneration:REBA study. J Clin Med 10:2758, 2021
15)Monés J, Srivastava SK, Jaffe GJ et al:Risk of inflammation, retinal vasculitis, retinal occlusion-related events with brolucizumab:post hoc review of HAWK and HARRIER. Ophthalmology 128:1050-1059, 2021
16)Maruko I, Okada AA, Iida T et al:Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration:a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol 259:2857-2859, 2021